HEADER PEPTIDE BINDING PROTEIN 16-OCT-20 7AP6 TITLE STRUCTURE OF SARS-COV-2 MAIN PROTEASE BOUND TO MUT056399. COMPND MOL_ID: 1; COMPND 2 MOLECULE: 3C-LIKE PROTEINASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: 3CL-PRO,3CLP,MAIN PROTEASE,MPRO,NON-STRUCTURAL PROTEIN 5, COMPND 5 NSP5,SARS CORONAVIRUS MAIN PROTEINASE; COMPND 6 EC: 3.4.22.69; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS SOURCE 3 2; SOURCE 4 ORGANISM_COMMON: 2019-NCOV, SARS-COV-2; SOURCE 5 ORGANISM_TAXID: 2697049; SOURCE 6 GENE: REP, 1A-1B; SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS SARS-COV-2, MPRO, COVID-!9, PEPTIDE BINDING PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR W.EWERT,S.GUENTHER,P.REINKE,D.OBERTHUER,O.YEFANOV,L.GELISIO,H.GINN, AUTHOR 2 J.LIESKE,M.DOMARACKY,W.BREHM,A.RAHMANI MASHOUR,T.A.WHITE,J.KNOSKA, AUTHOR 3 G.PENA ESPERANZA,F.KOUA,A.TOLSTIKOVA,M.GROESSLER,P.FISCHER, AUTHOR 4 V.HENNICKE,H.FLECKENSTEIN,F.TROST,M.GALCHENKOVA,Y.GEVORKOV,C.LI, AUTHOR 5 S.AWEL,L.X.PAULRAJ,N.ULLAH,S.FALKE,B.ALVES FRANCA,M.SCHWINZER, AUTHOR 6 H.BROGNARO,N.WERNER,M.PERBANDT,H.TIDOW,B.SEYCHELL,T.BECK,S.MEIER, AUTHOR 7 J.J.DOYLE,H.GISELER,D.MELO,I.DUNKEL,T.J.LANE,A.PECK,S.SAOUANE, AUTHOR 8 J.HAKANPAEAE,J.MEYER,H.NOEI,P.GRIBBON,B.ELLINGER,M.KUZIKOV,M.WOLF, AUTHOR 9 L.ZHANG,C.EHRT,J.PLETZER-ZELGERT,J.WOLLENHAUPT,C.FEILER,M.WEISS, AUTHOR 10 E.C.SCHULZ,P.MEHRABI,B.NORTON-BAKER,C.SCHMIDT,K.LORENZEN,R.SCHUBERT, AUTHOR 11 H.HAN,A.CHARI,Y.FERNANDEZ GARCIA,D.TURK,R.HILGENFELD,M.RAREY, AUTHOR 12 A.ZALIANI,H.N.CHAPMAN,A.PEARSON,C.BETZEL,A.MEENTS REVDAT 5 31-JAN-24 7AP6 1 JRNL REVDAT 4 19-MAY-21 7AP6 1 JRNL REVDAT 3 14-APR-21 7AP6 1 COMPND SOURCE JRNL REVDAT 2 09-DEC-20 7AP6 1 JRNL REVDAT 1 02-DEC-20 7AP6 0 JRNL AUTH S.GUNTHER,P.Y.A.REINKE,Y.FERNANDEZ-GARCIA,J.LIESKE,T.J.LANE, JRNL AUTH 2 H.M.GINN,F.H.M.KOUA,C.EHRT,W.EWERT,D.OBERTHUER,O.YEFANOV, JRNL AUTH 3 S.MEIER,K.LORENZEN,B.KRICHEL,J.D.KOPICKI,L.GELISIO,W.BREHM, JRNL AUTH 4 I.DUNKEL,B.SEYCHELL,H.GIESELER,B.NORTON-BAKER, JRNL AUTH 5 B.ESCUDERO-PEREZ,M.DOMARACKY,S.SAOUANE,A.TOLSTIKOVA, JRNL AUTH 6 T.A.WHITE,A.HANLE,M.GROESSLER,H.FLECKENSTEIN,F.TROST, JRNL AUTH 7 M.GALCHENKOVA,Y.GEVORKOV,C.LI,S.AWEL,A.PECK,M.BARTHELMESS, JRNL AUTH 8 F.SCHLUNZEN,P.LOURDU XAVIER,N.WERNER,H.ANDALEEB,N.ULLAH, JRNL AUTH 9 S.FALKE,V.SRINIVASAN,B.A.FRANCA,M.SCHWINZER,H.BROGNARO, JRNL AUTH10 C.ROGERS,D.MELO,J.J.ZAITSEVA-DOYLE,J.KNOSKA, JRNL AUTH11 G.E.PENA-MURILLO,A.R.MASHHOUR,V.HENNICKE,P.FISCHER, JRNL AUTH12 J.HAKANPAA,J.MEYER,P.GRIBBON,B.ELLINGER,M.KUZIKOV,M.WOLF, JRNL AUTH13 A.R.BECCARI,G.BOURENKOV,D.VON STETTEN,G.POMPIDOR,I.BENTO, JRNL AUTH14 S.PANNEERSELVAM,I.KARPICS,T.R.SCHNEIDER,M.M.GARCIA-ALAI, JRNL AUTH15 S.NIEBLING,C.GUNTHER,C.SCHMIDT,R.SCHUBERT,H.HAN,J.BOGER, JRNL AUTH16 D.C.F.MONTEIRO,L.ZHANG,X.SUN,J.PLETZER-ZELGERT, JRNL AUTH17 J.WOLLENHAUPT,C.G.FEILER,M.S.WEISS,E.C.SCHULZ,P.MEHRABI, JRNL AUTH18 K.KARNICAR,A.USENIK,J.LOBODA,H.TIDOW,A.CHARI,R.HILGENFELD, JRNL AUTH19 C.UETRECHT,R.COX,A.ZALIANI,T.BECK,M.RAREY,S.GUNTHER,D.TURK, JRNL AUTH20 W.HINRICHS,H.N.CHAPMAN,A.R.PEARSON,C.BETZEL,A.MEENTS JRNL TITL X-RAY SCREENING IDENTIFIES ACTIVE SITE AND ALLOSTERIC JRNL TITL 2 INHIBITORS OF SARS-COV-2 MAIN PROTEASE. JRNL REF SCIENCE V. 372 642 2021 JRNL REFN ESSN 1095-9203 JRNL PMID 33811162 JRNL DOI 10.1126/SCIENCE.ABF7945 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH S.GUENTHER,P.Y.A.,REINKE,Y.,FERNANDEZ-GARCIA,J.,LIESKE,T.J., REMARK 1 AUTH 2 LANE,H.M.,GINN,F.H.M.,KOUA,C.,EHRT,W.,EWERT,D.,OBERTHUER,O., REMARK 1 AUTH 3 YEFANOV,S.,MEIER,K.,LORENZEN,B.,KRICHEL,J.D.,KOPICKI,L., REMARK 1 AUTH 4 GELISIO,W.,BREHM,I.,DUNKEL,B.,SEYCHELL,H.,GIESELER,B., REMARK 1 AUTH 5 NORTON-BAKER,B.,ESCUDERO-PEREZ,M.,DOMARACKY,S.,SAOUANE,A., REMARK 1 AUTH 6 TOLSTIKOVA,T.A.,WHITE,A.,HANLE,M.,GROESSLER,H.,FLECKENSTEIN, REMARK 1 AUTH 7 F.,TROST,M.,GALCHENKOVA,Y.,GEVORKOV,C.,LI,S.,AWEL,A.PECK,M., REMARK 1 AUTH 8 BARTHELMESS,F.,SCHLUENZEN,L.X.,PAULRAJ,N.,WERNER,H., REMARK 1 AUTH 9 ANDALEEB,N.,ULLAH,S.,FALKE,V.,SRINIVASAN,B.,FRANCA,M., REMARK 1 AUTH10 SCHWINZER,H.,BROGNARO,C.,ROGERS,D.,MELO,J.J.,DOYLE,J., REMARK 1 AUTH11 KNOSKA,G.E.,PENA MURILLO,A.,RAHMANI MASHHOUR,F.,GUICKING,V., REMARK 1 AUTH12 HENNICKE,P.,FISCHER,J.,HAKANPAEAE,J.,MEYER,P.,GRIBBON,B., REMARK 1 AUTH13 ELLINGER,M.,KUZIKOV,M.,WOLF,G.,BURENKOV,D.,VON STETTEN,G., REMARK 1 AUTH14 POMPIDOR,I.,BENTO,S.,PANNEERSELVAM,I.,KARPICS,T.R., REMARK 1 AUTH15 SCHNEIDER,M.,GARCIA ALAI,S.,NIEBLING,C.,GUENTHER,C.,SCHMIDT, REMARK 1 AUTH16 R.,SCHUBERT,H.,HAN,J.,BOGER,D.,MONTEIRO,L.,ZHANG,X.,SUN,J., REMARK 1 AUTH17 PLETZER-ZELGERT,J.,WOLLENHAUPT,C.,FEILER,M.,WEISS,E.C., REMARK 1 AUTH18 SCHULZ,P.,MEHRABI,K.,KARNICAR,A.,USENIK,J.,LOBODA,H.,TIDOW, REMARK 1 AUTH19 A.,CHARI,R.,HILGENFELD,C.,UETRECHT,R.,COX,A.,ZALIANI,T., REMARK 1 AUTH20 BECK,M.,RAREY,S.,GUENTHER,D.,TURK,W.,HINRICHS,H.N.,CHAPMAN, REMARK 1 AUTH21 A.,PEARSON,C.,BETZEL,A.MEENTS REMARK 1 TITL INHIBITION OF SARS-COV-2 MAIN PROTEASE BY ALLOSTERIC REMARK 1 TITL 2 DRUG-BINDING REMARK 1 REF BIORXIV 2020 REMARK 1 REFN ISSN 2692-8205 REMARK 1 DOI 10.1101/2020.11.12.378422 REMARK 2 REMARK 2 RESOLUTION. 1.78 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.18-3855_9999 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : GEOSTD + MONOMER LIBRARY + CDL V1.2 REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.78 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 47.78 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.440 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 3 NUMBER OF REFLECTIONS : 24700 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.200 REMARK 3 R VALUE (WORKING SET) : 0.198 REMARK 3 FREE R VALUE : 0.237 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.030 REMARK 3 FREE R VALUE TEST SET COUNT : 1242 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 47.7800 - 3.7000 1.00 2677 152 0.1600 0.1799 REMARK 3 2 3.7000 - 2.9400 1.00 2650 123 0.1724 0.2012 REMARK 3 3 2.9400 - 2.5700 1.00 2598 147 0.1998 0.2744 REMARK 3 4 2.5700 - 2.3300 1.00 2581 158 0.2024 0.2833 REMARK 3 5 2.3300 - 2.1700 1.00 2592 145 0.2101 0.2635 REMARK 3 6 2.1700 - 2.0400 1.00 2598 120 0.2319 0.2586 REMARK 3 7 2.0400 - 1.9400 1.00 2637 118 0.2556 0.3044 REMARK 3 8 1.9400 - 1.8500 1.00 2580 147 0.2913 0.3184 REMARK 3 9 1.8500 - 1.7800 0.99 2545 132 0.3271 0.3624 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.276 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 28.079 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 22.39 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 30.67 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.006 2521 REMARK 3 ANGLE : 0.743 3436 REMARK 3 CHIRALITY : 0.047 379 REMARK 3 PLANARITY : 0.006 451 REMARK 3 DIHEDRAL : 20.130 907 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7AP6 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 20-OCT-20. REMARK 100 THE DEPOSITION ID IS D_1292111834. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 04-APR-20 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : PETRA III, DESY REMARK 200 BEAMLINE : P11 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0332 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DIALS REMARK 200 DATA SCALING SOFTWARE : DIALS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 24700 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.780 REMARK 200 RESOLUTION RANGE LOW (A) : 47.780 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 4.4600 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.78 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.84 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 6YB7 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 36.14 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.93 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CO-CRYSTALLIZATION WITH THE COMPOUNDS REMARK 280 WAS ACHIEVED BY EQULIBRATING A 6.25 MG/ML PROTEIN SOLUTION IN 20 REMARK 280 MM HEPES BUFFER (PH 7.8) CONTAINING 1 MM DTT, 1MM EDTA, AND 150 REMARK 280 MM NACL AGAINST A RESERVOIR SOLUTION OF 100 MM MIB BUFFER (2:3:3 REMARK 280 MOLAR RATIO OF MALONIC ACID, IMIDAZOLE, AND BORIC ACID), PH 7.5, REMARK 280 CONTAINING 25% V/V PEG 1500 AND 5% V/V DMSO. PRIOR TO REMARK 280 CRYSTALLIZATION COMPOUND SOLUTIONS IN DMSO WERE DRIED ONTO THE REMARK 280 WELLS OF SWISSCI 96-WELL PLATES. TO ACHIEVE REPRODUCIBLE CRYSTAL REMARK 280 GROWTH SEEDING WAS USED. CRYSTALS APPEARED WITHIN A FEW HOURS REMARK 280 AND REACHED THEIR FINAL SIZE AFTER 2 -3 DAYS., COUNTER-DIFFUSION, REMARK 280 TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 56.68150 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 26.49550 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 56.68150 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 26.49550 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3170 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 25100 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -16.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 CZ ARG A 217 LIES ON A SPECIAL POSITION. REMARK 375 NH1 ARG A 217 LIES ON A SPECIAL POSITION. REMARK 375 HOH A 694 LIES ON A SPECIAL POSITION. REMARK 375 HOH A 704 LIES ON A SPECIAL POSITION. REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 306 CG CD OE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 33 -125.88 53.92 REMARK 500 ASN A 51 73.46 -150.93 REMARK 500 ASN A 84 -116.02 54.42 REMARK 500 TYR A 154 -85.54 69.55 REMARK 500 TYR A 154 -85.56 69.55 REMARK 500 HIS A 164 -50.95 -123.50 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A 772 DISTANCE = 6.36 ANGSTROMS REMARK 525 HOH A 773 DISTANCE = 6.45 ANGSTROMS REMARK 525 HOH A 774 DISTANCE = 7.39 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue RQN A 401 DBREF 7AP6 A 1 306 UNP P0DTD1 R1AB_SARS2 3264 3569 SEQRES 1 A 306 SER GLY PHE ARG LYS MET ALA PHE PRO SER GLY LYS VAL SEQRES 2 A 306 GLU GLY CYS MET VAL GLN VAL THR CYS GLY THR THR THR SEQRES 3 A 306 LEU ASN GLY LEU TRP LEU ASP ASP VAL VAL TYR CYS PRO SEQRES 4 A 306 ARG HIS VAL ILE CYS THR SER GLU ASP MET LEU ASN PRO SEQRES 5 A 306 ASN TYR GLU ASP LEU LEU ILE ARG LYS SER ASN HIS ASN SEQRES 6 A 306 PHE LEU VAL GLN ALA GLY ASN VAL GLN LEU ARG VAL ILE SEQRES 7 A 306 GLY HIS SER MET GLN ASN CYS VAL LEU LYS LEU LYS VAL SEQRES 8 A 306 ASP THR ALA ASN PRO LYS THR PRO LYS TYR LYS PHE VAL SEQRES 9 A 306 ARG ILE GLN PRO GLY GLN THR PHE SER VAL LEU ALA CYS SEQRES 10 A 306 TYR ASN GLY SER PRO SER GLY VAL TYR GLN CYS ALA MET SEQRES 11 A 306 ARG PRO ASN PHE THR ILE LYS GLY SER PHE LEU ASN GLY SEQRES 12 A 306 SER CYS GLY SER VAL GLY PHE ASN ILE ASP TYR ASP CYS SEQRES 13 A 306 VAL SER PHE CYS TYR MET HIS HIS MET GLU LEU PRO THR SEQRES 14 A 306 GLY VAL HIS ALA GLY THR ASP LEU GLU GLY ASN PHE TYR SEQRES 15 A 306 GLY PRO PHE VAL ASP ARG GLN THR ALA GLN ALA ALA GLY SEQRES 16 A 306 THR ASP THR THR ILE THR VAL ASN VAL LEU ALA TRP LEU SEQRES 17 A 306 TYR ALA ALA VAL ILE ASN GLY ASP ARG TRP PHE LEU ASN SEQRES 18 A 306 ARG PHE THR THR THR LEU ASN ASP PHE ASN LEU VAL ALA SEQRES 19 A 306 MET LYS TYR ASN TYR GLU PRO LEU THR GLN ASP HIS VAL SEQRES 20 A 306 ASP ILE LEU GLY PRO LEU SER ALA GLN THR GLY ILE ALA SEQRES 21 A 306 VAL LEU ASP MET CYS ALA SER LEU LYS GLU LEU LEU GLN SEQRES 22 A 306 ASN GLY MET ASN GLY ARG THR ILE LEU GLY SER ALA LEU SEQRES 23 A 306 LEU GLU ASP GLU PHE THR PRO PHE ASP VAL VAL ARG GLN SEQRES 24 A 306 CYS SER GLY VAL THR PHE GLN HET RQN A 401 34 HETNAM RQN 4-(4-ETHYL-5-FLUORANYL-2-OXIDANYL-PHENOXY)-3-FLUORANYL- HETNAM 2 RQN BENZAMIDE FORMUL 2 RQN C15 H13 F2 N O3 FORMUL 3 HOH *274(H2 O) HELIX 1 AA1 SER A 10 GLY A 15 1 6 HELIX 2 AA2 HIS A 41 CYS A 44 5 4 HELIX 3 AA3 THR A 45 LEU A 50 5 6 HELIX 4 AA4 ASN A 53 ARG A 60 1 8 HELIX 5 AA5 LYS A 61 HIS A 64 5 4 HELIX 6 AA6 ILE A 200 ASN A 214 1 15 HELIX 7 AA7 THR A 226 TYR A 237 1 12 HELIX 8 AA8 THR A 243 LEU A 250 1 8 HELIX 9 AA9 LEU A 250 GLY A 258 1 9 HELIX 10 AB1 ALA A 260 GLY A 275 1 16 HELIX 11 AB2 THR A 292 GLY A 302 1 11 SHEET 1 AA1 7 VAL A 73 LEU A 75 0 SHEET 2 AA1 7 PHE A 66 ALA A 70 -1 N VAL A 68 O LEU A 75 SHEET 3 AA1 7 MET A 17 CYS A 22 -1 N THR A 21 O LEU A 67 SHEET 4 AA1 7 THR A 25 LEU A 32 -1 O GLY A 29 N VAL A 18 SHEET 5 AA1 7 VAL A 35 PRO A 39 -1 O TYR A 37 N LEU A 30 SHEET 6 AA1 7 VAL A 86 VAL A 91 -1 O LEU A 89 N VAL A 36 SHEET 7 AA1 7 VAL A 77 GLN A 83 -1 N ILE A 78 O LYS A 90 SHEET 1 AA2 5 LYS A 100 PHE A 103 0 SHEET 2 AA2 5 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA2 5 VAL A 148 ASP A 153 -1 N ASN A 151 O SER A 158 SHEET 4 AA2 5 THR A 111 TYR A 118 -1 N SER A 113 O PHE A 150 SHEET 5 AA2 5 SER A 121 ALA A 129 -1 O CYS A 128 N PHE A 112 SHEET 1 AA3 3 LYS A 100 PHE A 103 0 SHEET 2 AA3 3 CYS A 156 GLU A 166 1 O VAL A 157 N LYS A 100 SHEET 3 AA3 3 HIS A 172 THR A 175 -1 O ALA A 173 N MET A 165 SITE 1 AC1 12 HIS A 41 MET A 49 PHE A 140 LEU A 141 SITE 2 AC1 12 ASN A 142 CYS A 145 HIS A 163 HIS A 164 SITE 3 AC1 12 MET A 165 GLU A 166 ASP A 187 HOH A 602 CRYST1 113.363 52.991 44.510 90.00 102.92 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.008821 0.000000 0.002024 0.00000 SCALE2 0.000000 0.018871 0.000000 0.00000 SCALE3 0.000000 0.000000 0.023051 0.00000